www.hivandhepatitis.com

EACS 2015: Does Low-level HIV Viral Load Raise the Risk of Disease Progression and Comorbidities?

HIV-positive people with detectable but low viral load -- in the range of 50 to 500 or 1000 copies/mL -- may continue to have a higher risk of AIDS-related events, but their likelihood of experiencing serious non-AIDS events including heart, liver, and kidney disease did not appear to increase, according to a pair of Italian studies presented at the 15th European AIDS Conference last month in Barcelona.

It is well known that effective combination antiretroviral therapy (ART) that suppresses HIV replication dramatically reduces disease progression and improves survival. Recent findings from the large START trial showed that people who initiate treatment soon after diagnosis had a lower risk of both AIDS-related illnesses and non-AIDS events and death compared to those who waited until their CD4 T-cell count fell.

A small proportion of people with HIV have persistently detectable but low viral load despite treatment, and the effects of low-level viremia are not fully understood. Even a low level of ongoing viral replication can lead to increased immune activation and inflammation, which may contribute to non-AIDS comorbidities such as heart disease and cancer. However, large observational studies (including the Dutch ATHENA cohort and the ART Cohort Collaboration) previously have not seen an association between low-level virus and increased risk of AIDS, non-AIDS illness, or death. 

Andrea Antinori and fellow investigators with the ICONA Foundation Study Cohort estimated 3-month incidence of AIDS-related events, severe non-AIDS events, or death among people with current low-level viremia compared to those with viral loads below 50 copies/mL.

The analysis included 7277 participants in the Italian ICONA cohort who had at least 1 person-year follow-up spent with a viral load in the range of 0 to 1000 copies/mL at least 6 months after starting first-line combination ART. Three-quarters were men, most were white, the median age was 37 years, and 18% were coinfected with hepatitis C. The median CD4 count at ART initiation was approximately 300 cells/mm³ and 13% had been diagnosed with AIDS. The most common ART regimen was efavirenz (Sustiva) plus tenofovir/emtricitabine (the drugs in Truvada), but a wide range of other drugs were also used.

The researchers classified participants into 4 groups according to viral load at 6 months after starting ART:

• 0-50 copies/mL (n=3919);
• 51-200 copies/mL (n=1811);
• 201-500 copies/mL (n=1117);
• 500-1000 copies/mL (n=430).

They compared 2 composite endpoints across the viral load groups: AIDS or death due to any cause, and serious non-AIDS events according to the definition used in the SMART study (major cardiovascular, kidney, or liver disease) and death due to any cause, over the course of 3 months.

Results

• 204 AIDS-related events or deaths occurred during 28,429 person-years of follow-up.
• Incidence rates of AIDS-related events or death were 0.52, 1.25, 1.91, and 1.06 per 100 person-years for participants with viral loads of 0-50, 51-200, 201-500, and 500-1000 copies/mL, respectively.
• The adjusted risk of AIDS-related events or death was 1.74 (74% increase), 2.30 (more than double the risk), and 1.30 (30% increase) for people with 51-200, 201-500, and 500-1000 copies/mL, respectively, compared to those with 0-50 copies/mL; these differences were statistically significant for the 51-200 and 201-500 groups, but not for the 500-1000 group.
• 438 serious non-AIDS events or deaths occurred during follow-up.
• Incidence rates of serious non-AIDS events or death were 1.46, 1.77, 1.69, and 2.56 for the respective viral load groups.
• The adjusted risk of serious non-AIDS events or death was 1.09 (little change), 1.00 (no difference), and 1.54 (54% increase) for people with 51-200, 201-500, and 500-1000 copies/mL, respectively, none of which were statistically significant.

"Low-level viremia, in the range of 51-500 copies/mL, was associated with an independent risk of developing a new AIDS diagnosis, which was up to 2.3 fold higher than that observed in the presence of suppressed viral load," the researchers concluded. "Conversely, low-level viremia did seem to predict a more elevated risk of serious non-AIDS events."

They noted, however, that the viral load categories in this study were based on current levels and could not account for sustained periods of low-level viral replication. Occasional viral "blips" are not uncommon during treatment, but persistent viremia is a greater concern. They also said the short (3-month) follow-up period may have underestimated long-term effects on clinical endpoints.

These results, they added, "may be useful to plan analyses aimed at better defining threshold of virological failure valid for clinical purposes and to eventually optimize treatment strategies."

Cardiovascular Events

In the second study, Silvia Costarelli from San Gerardo Hospital in Monza, Italy, and colleagues with the Italian MASTER Cohort looked at the association between persistent low-level viremia (HIV RNA between 50 and 400 copies/mL) and increased risk of cardiovascular disease events.

This analysis included 4393 people who achieved viral load below 50 copies/mL for at least 6 months after ART initiation. About 70% were men, most were Italian, and the median age at ART initiation was approximately 40 years. They had relatively advanced HIV disease, with a median CD4 count below 300 cells/mm³. Underlying cardiovascular risk was generally low, with only about 1% having prior cardiovascular events.

A majority of 3576 patients maintained full viral suppression, but 574 experienced treatment failure with viral rebound to >400 copies/mL and 243 had persistent low-level viremia on 2 consecutive tests.

During follow up there were 45 cardiovascular events, 57 AIDS events, and 93 deaths among people with ongoing viral suppression; 18, 53, and 37, respectively, among people with viral rebound, and 6, 5, and 4, respectively, among people with persistent low-level viremia.

The researchers considered 2 composite endpoints: first cardiovascular event, AIDS-related event, or death; and first cardiovascular event or death, ignoring AIDS.

For the first endpoint, unadjusted incidence rates were 11.7, 21.6, and 9.3 per 1000 person years, respectively, for people with full viral suppression, viral rebound, and persistent low-level viremia. For the second endpoint, incidence rates were 8.6, 11.6, and 9.0, respectively. That is, the risk of adverse outcomes was greater -- nearly 2-fold higher -- for people with viral rebound when AIDS was considered, but not when considering only cardiovascular events or death.

In a multivariate analysis, patients with viral rebound had a significantly higher risk for both the first and second endpoints compared to people with ongoing viral suppression (hazard ratio 2.15 and 1.5, respectively). However, persistent low-level viremia was not associated with significantly different hazard rates.

"Our results suggest that persistent low-level viremia does not influence cardiovascular disease," the investigators concluded. "Moreover, in our setting, persistent low-level viremia does not even influence AIDS or death.

In summary, incidence of cardiovascular events, AIDS, and death were similar for people with ongoing viral suppression and those with persistent low-level viremia in the MASTER study, suggesting that low-level viral load does not increase the risk of either AIDS or non-AIDS events. This conflicts with the ICONA findings, which did see a higher risk of AIDS among people with low but detectable viral load.

11/4/15

References

A Antinori, A Cozzi Lepri, A Ammassari, et al. Low-level Viremia (LLV) Ranging from 50 to 500 Copies/mL is Associated to an Increased Risk of AIDS Events in the Icona Foundation Cohort. 15th European AIDS Conference. Barcelona, October 21-24, 2015. Abstract PS4/2.

S Costarelli, D Bernasconi, G Lapadula, et al. Persistent HIV Low-level Viremia and Cardiovascular Risk. 15th European AIDS Conference. Barcelona, October 21-24, 2015. Abstract PE12/10.